This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Powerful perspectives
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Data & publication
Safety and clinical efficacy of roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase Inhibitor delta (PI3Kδ)
Press coveragepharmaphorum — Uveal melanoma: a new generation of therapies offers hope for patients
Press coverageImmuno-Oncology Insights — Navigating the complexities of immunotherapy: unraveling novel targets & pathways
Press coverageDrug Target Review — Combining autotaxin and TGF-β inhibitors in cancer
Press releaseiOnctura to present research on roginolisib and IOA-359 at ASH
Press coverageLabiotech — Could this be the start of a new era for PI3K drugs?
Press releaseiOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ
Press releaseNew research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer
Data & publicationAutotaxin secretion is a stromal mechanism of adaptive resistance to TGFβ inhibition in pancreatic ductal adenocarcinoma
Press coverageDrug Discovery World — Meet the researcher: Giusy Di Conza
Data & publicationNon-clinical toxicology evaluation of the novel non-ATP competitive oral PI3 kinase delta inhibitor roginolisib
Press coveragepharmaphorum — Realising the potential of autotaxin inhibition in cancer
Looking for media
resources?